Medicine and Dentistry
Placebo
100%
Irbesartan
65%
Hemodialysis
60%
Supplementation
54%
Chronic Kidney Disease
54%
Heart Rate Variability
39%
Intervention Trial
34%
Angiotensin Receptor Antagonist
34%
Kidney Function
31%
Vitamin K Deficiency
27%
Systolic Blood Pressure
25%
Cardiovascular Disease
25%
Electroconvulsive Therapy
25%
Autonomic Function
25%
Heart Failure
25%
Diabetes
25%
Placebo-Controlled Study
25%
Fatty Acid
25%
Cardiovascular System
25%
Receptor Blocking
25%
Hemodynamic
25%
Randomized Controlled Trial
25%
Polyunsaturated Fatty Acid
25%
Adverse Event
23%
Glomerular Filtration Rate
21%
Blood Pressure
20%
Vascular Resistance
20%
Drug Therapy
17%
Ultrafiltration
16%
Antihypertensive Agent
16%
Antihypertensive Therapy
16%
Stroke Volume
15%
Heart Output
15%
Mean Arterial Pressure
15%
Central Blood Volume
15%
Biological Marker
15%
Epileptic Absence
15%
Thrombin
15%
Osteocalcin
14%
Pulse Wave Velocity
13%
Side Effect
12%
C Reactive Protein
10%
Hypotension
10%
Vitamin K-Dependent Coagulation Factor
10%
Procoagulant
10%
Renin Angiotensin Aldosterone System
9%
Renal Replacement Therapy
8%
Menaquinone
7%
Atherosclerosis
7%
Coronary Artery Calcification
7%
Pharmacology, Toxicology and Pharmaceutical Science
Omega-3 Fatty Acid
75%
Placebo
65%
Chronic Kidney Failure
54%
Irbesartan
50%
Hemodialysis
37%
Intervention Trial
30%
Fatty Acid
28%
Antihypertensive Agent
27%
Sudden Cardiac Death
26%
Polyunsaturated Fatty Acid
25%
Low Density Lipoprotein
25%
Haptoglobin
25%
End Stage Renal Disease
25%
Atrial Fibrillation
25%
Angiotensin Receptor Antagonist
25%
Angiotensin Receptor
25%
Intervention Study
25%
Artery Calcification
25%
Vitamin D
25%
Heart Failure
25%
Hip Fracture
25%
Side Effect
25%
Vitamin K Deficiency
25%
Hypotension
16%
Pharmacotherapy
12%
Antidepressant
12%
Remission
12%
Depressed Blood Pressure
11%
SLCO1B1
8%
Aldosterone
6%
Hormone Precursor
6%
Renin
6%
Catecholamine
6%
Angiotensin
6%
Docosahexaenoic Acid
6%
Icosapentaenoic Acid
6%
Parathyroid Hormone
5%
Comorbidity
5%
Serum Albumin
5%
Phospholipid
5%
Antiarrhythmic Agent
5%
Cardiovascular Disease
5%
Tolerability
5%
Heart Arrhythmia
5%
Heart Ventricle Arrhythmia
5%
Antihypertensive Therapy
5%
Keyphrases
Central Hemodynamics
25%
Intradialytic
25%
Haptoglobin
25%
Haptoglobin Genotype
25%
Irbesartan
25%
Haptoglobin Phenotype
25%
Renin-angiotensin System Blockade
25%
Angiotensin Receptor Blockade
25%
Cardiac Autonomic Function
25%
Vitamin K Supplementation
25%
Arterial Calcification
25%
Newly Diagnosed Hypertension
25%
Dosing Guidelines
25%
Total Peripheral Resistance
20%
Central Blood Volume
15%
Heart Rate Variability
14%
Atherosclerosis
10%
Rate Decline
10%
Urine Volume
10%
MK-7
10%
Intradialytic Hypotension
10%
Maintenance Pharmacotherapy
8%
High-risk Cases
8%
Modified Electroconvulsive Therapy
8%
Chronic Kidney Disease Patients
7%
SDANN
7%
Angiotensin II (Ang II)
7%
Dialysis Vintage
7%
Coronary Arterial Calcification
7%
Vitamin K Status
7%
K-group
7%
Procoagulant Effect
7%
Brachial Blood Pressure
6%
Arterial Stiffness
6%
Antihypertensive Medication
6%
SAFIR
6%
Renin-angiotensin-aldosterone System
6%
Central Aortic Pressure
6%
Urinary Catecholamines
6%
Ultrafiltration Volume
6%
Blood Pressure Target
6%
Blood Pressure Lowering
6%
Prohormone
6%
Residual Renal Function
6%
Carotid-femoral Pulse Wave Velocity (cfPWV)
6%
Low Blood Pressure
6%
Means-end
5%
Dialysis Session
5%
Antihypertensive Therapy
5%
One Year Period
5%